ATE508747T1 - C-kit kinase-hemmer - Google Patents

C-kit kinase-hemmer

Info

Publication number
ATE508747T1
ATE508747T1 AT04719054T AT04719054T ATE508747T1 AT E508747 T1 ATE508747 T1 AT E508747T1 AT 04719054 T AT04719054 T AT 04719054T AT 04719054 T AT04719054 T AT 04719054T AT E508747 T1 ATE508747 T1 AT E508747T1
Authority
AT
Austria
Prior art keywords
kit kinase
kinase inhibitors
discovered
general formula
inhibitory activity
Prior art date
Application number
AT04719054T
Other languages
English (en)
Inventor
Yuji Yamamoto
Tatsuo Watanabe
Masayuki Okada
Akihiko Tsuruoka
Original Assignee
Eisai R&D Man Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Eisai R&D Man Co Ltd filed Critical Eisai R&D Man Co Ltd
Application granted granted Critical
Publication of ATE508747T1 publication Critical patent/ATE508747T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/48—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pulmonology (AREA)
  • Epidemiology (AREA)
  • Hematology (AREA)
  • Immunology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Diabetes (AREA)
  • Obesity (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Quinoline Compounds (AREA)
AT04719054T 2003-03-10 2004-03-10 C-kit kinase-hemmer ATE508747T1 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2003062823 2003-03-10
JP2003302803 2003-08-27
PCT/JP2004/003087 WO2004080462A1 (ja) 2003-03-10 2004-03-10 c-Kitキナーゼ阻害剤

Publications (1)

Publication Number Publication Date
ATE508747T1 true ATE508747T1 (de) 2011-05-15

Family

ID=32992931

Family Applications (1)

Application Number Title Priority Date Filing Date
AT04719054T ATE508747T1 (de) 2003-03-10 2004-03-10 C-kit kinase-hemmer

Country Status (5)

Country Link
US (1) US7994159B2 (de)
EP (1) EP1604665B1 (de)
JP (1) JPWO2004080462A1 (de)
AT (1) ATE508747T1 (de)
WO (1) WO2004080462A1 (de)

Families Citing this family (68)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR100600550B1 (ko) 2000-10-20 2006-07-13 에자이 가부시키가이샤 질소 함유 방향환 유도체
EP1604665B1 (de) 2003-03-10 2011-05-11 Eisai R&D Management Co., Ltd. C-kit kinase-hemmer
JP4303726B2 (ja) 2003-11-11 2009-07-29 エーザイ・アール・アンド・ディー・マネジメント株式会社 ウレア誘導体およびその製造方法
HUE025742T2 (hu) 2003-12-25 2016-04-28 Eisai R&D Man Co Ltd 4-(3-klór-4-(ciklopropilamino-karbonil)aminofenoxi)-7-metoxi-6-kinolin-karboxamid vagy szolvátja sójának kristálya és eljárás elõállításukra
US8969379B2 (en) * 2004-09-17 2015-03-03 Eisai R&D Management Co., Ltd. Pharmaceutical compositions of 4-(3-chloro-4-(cyclopropylaminocarbonyl)aminophenoxy)-7=methoxy-6-quinolinecarboxide
US8247419B2 (en) * 2005-06-09 2012-08-21 Bristol-Myers Squibb Company Methods of identifying and treating individuals exhibiting mutant kit protein
KR100951607B1 (ko) * 2005-06-23 2010-04-09 에자이 알앤드디 매니지먼트 가부시키가이샤 4-(3-클로로-4-(시클로프로필아미노카르보닐)아미노페녹시)-7-메톡시-6-퀴놀린카르복사미드의 비정질 염 및 그 제조방법
US7550483B2 (en) 2005-06-23 2009-06-23 Eisai R&D Management Co., Ltd. Amorphous salt of 4-(3-chloro-4-(cyclopropylaminocarbonyl)aminophenoxy)-7-methoxy-6-quinolinecarboxamide and process for preparing the same
JP5066446B2 (ja) * 2005-08-01 2012-11-07 エーザイ・アール・アンド・ディー・マネジメント株式会社 血管新生阻害物質の効果を予測する方法
JP4989476B2 (ja) 2005-08-02 2012-08-01 エーザイ・アール・アンド・ディー・マネジメント株式会社 血管新生阻害物質の効果を検定する方法
KR101353763B1 (ko) 2005-11-07 2014-01-21 에자이 알앤드디 매니지먼트 가부시키가이샤 혈관 신생 저해 물질과 c―kit 키나아제 저해 물질의병용
US20090247576A1 (en) * 2005-11-22 2009-10-01 Eisai R & D Management Co., Ltd. Anti-tumor agent for multiple myeloma
CN104706637A (zh) * 2006-05-18 2015-06-17 卫材R&D管理有限公司 针对甲状腺癌的抗肿瘤剂
US20090203693A1 (en) 2006-06-29 2009-08-13 Eisai R & D Management Co., Ltd. Therapeutic agent for liver fibrosis
JP5368096B2 (ja) 2006-08-28 2013-12-18 エーザイ・アール・アンド・ディー・マネジメント株式会社 未分化型胃癌に対する抗腫瘍剤
WO2008115300A1 (en) * 2006-12-01 2008-09-25 Apocell, Inc. C-kit phosphorylation in cancer
WO2008093855A1 (ja) 2007-01-29 2008-08-07 Eisai R & D Management Co., Ltd. 未分化型胃癌治療用組成物
CA2704000C (en) 2007-11-09 2016-12-13 Eisai R&D Management Co., Ltd. Combination of anti-angiogenic substance and anti-tumor platinum complex
WO2009096377A1 (ja) * 2008-01-29 2009-08-06 Eisai R & D Management Co., Ltd. 血管阻害物質とタキサンとの併用
CA2771403C (en) * 2009-08-19 2015-02-24 Eisai R&D Management Co. Ltd. Quinoline derivative-containing pharmaceutical composition
CN102958523B (zh) 2010-06-25 2014-11-19 卫材R&D管理有限公司 使用具有激酶抑制作用的组合的抗肿瘤剂
AU2012246490B2 (en) 2011-04-18 2016-08-04 Eisai R&D Management Co., Ltd. Therapeutic agent for tumor
JP6038128B2 (ja) 2011-06-03 2016-12-07 エーザイ・アール・アンド・ディー・マネジメント株式会社 レンバチニブ化合物に対する甲状腺癌対象及び腎臓癌対象の反応性を予測及び評価するためのバイオマーカー
ES2573831T3 (es) 2011-07-27 2016-06-10 Ab Science Derivados de oxazol y tiazol como inhibidores selectivos de la proteína quinasa (C-kit)
JPWO2014098176A1 (ja) * 2012-12-21 2017-01-12 エーザイ・アール・アンド・ディー・マネジメント株式会社 キノリン誘導体のアモルファス及びその製造方法
CA2912219C (en) 2013-05-14 2021-11-16 Eisai R&D Management Co., Ltd. Biomarkers for predicting and assessing responsiveness of endometrial cancer subjects to lenvatinib compounds
EP3187491A4 (de) 2014-08-28 2018-08-01 Eisai R&D Management Co., Ltd. Hochreines chinolinderivat und verfahren zur herstellung davon
US20180028662A1 (en) 2015-02-25 2018-02-01 Eisai R&D Management Co., Ltd. Method for Suppressing Bitterness of Quinoline Derivative
KR20240064733A (ko) 2015-03-04 2024-05-13 머크 샤프 앤드 돔 코포레이션 암을 치료하기 위한 pd-1 길항제 및 vegfr/fgfr/ret 티로신 키나제 억제제의 조합
CA2988707C (en) 2015-06-16 2023-10-10 Eisai R&D Management Co., Ltd. Combination of cbp/catenin inhibitor and immune checkpoint inhibitor for treating cancer
CN108135894B (zh) 2015-08-20 2021-02-19 卫材R&D管理有限公司 肿瘤治疗剂
CN110072528B (zh) 2017-02-08 2022-04-26 卫材R&D管理有限公司 治疗肿瘤的药物组合物
WO2018157411A1 (zh) * 2017-02-28 2018-09-07 深圳市塔吉瑞生物医药有限公司 取代的含氮芳环化合物及其应用
WO2018212202A1 (en) 2017-05-16 2018-11-22 Eisai R&D Management Co., Ltd. Treatment of hepatocellular carcinoma
WO2019222075A1 (en) 2018-05-14 2019-11-21 Merck Sharp And Dohme Corp. Biomarkers for a combination therapy comprising lenvatinib and a pd-1 antagonist
CN110845408A (zh) * 2018-08-20 2020-02-28 润佳(苏州)医药科技有限公司 同位素富集的乐伐替尼
CA3129665A1 (en) 2019-03-21 2020-09-24 Onxeo A dbait molecule in combination with kinase inhibitor for the treatment of cancer
KR20220098759A (ko) 2019-11-08 2022-07-12 인쎄름 (엥스띠뛰 나씨오날 드 라 쌍떼 에 드 라 흐쉐르슈 메디깔) 키나제 억제제에 대해 내성을 획득한 암의 치료 방법
CN115362003B (zh) 2019-12-24 2024-03-22 卡尔那生物科学株式会社 二酰基甘油激酶调节化合物
WO2021148581A1 (en) 2020-01-22 2021-07-29 Onxeo Novel dbait molecule and its use
TWI890283B (zh) 2020-02-14 2025-07-11 美商基利科學股份有限公司 結合ccr8之抗體及融合蛋白及其用途
MX2023014762A (es) 2021-06-23 2024-01-15 Gilead Sciences Inc Compuestos moduladores de diacilglicerol quinasa.
JP7651018B2 (ja) 2021-06-23 2025-03-25 ギリアード サイエンシーズ, インコーポレイテッド ジアシルグリセロールキナーゼ調節化合物
CN117355531A (zh) 2021-06-23 2024-01-05 吉利德科学公司 二酰基甘油激酶调节化合物
EP4359413A1 (de) 2021-06-23 2024-05-01 Gilead Sciences, Inc. Diacylglyercolkinase modulierende verbindungen
CN113480479B (zh) * 2021-08-12 2022-08-02 上海爱博医药科技有限公司 脲类多靶点酪氨酸激酶抑制剂及其医药应用
EP4423078A1 (de) 2021-10-28 2024-09-04 Gilead Sciences, Inc. Pyrizidin-3(2h)-on-derivate
PE20241186A1 (es) 2021-10-29 2024-06-03 Gilead Sciences Inc Compuestos de cd73
CN118488948A (zh) 2021-12-22 2024-08-13 吉利德科学公司 Ikaros锌指家族降解剂及其用途
US20240124412A1 (en) 2021-12-22 2024-04-18 Gilead Sciences, Inc. Ikaros zinc finger family degraders and uses thereof
CA3248911A1 (en) 2022-01-28 2023-08-03 Gilead Sciences, Inc. POLY(ADENOSINE DIPHOSPHATE-RIBOSE) POLYMERASE 7 INHIBITORS
PL4245756T3 (pl) 2022-03-17 2025-02-17 Gilead Sciences, Inc. Środki degradujące palec cynkowy z rodziny ikaros i ich zastosowania
EP4511127A1 (de) 2022-04-21 2025-02-26 Gilead Sciences, Inc. Kras-g12d-modulierende verbindungen
WO2024006929A1 (en) 2022-07-01 2024-01-04 Gilead Sciences, Inc. Cd73 compounds
EP4638436A1 (de) 2022-12-22 2025-10-29 Gilead Sciences, Inc. Prmt5-inhibitoren und verwendungen davon
WO2024215754A1 (en) 2023-04-11 2024-10-17 Gilead Sciences, Inc. Kras modulating compounds
PE20260121A1 (es) 2023-04-21 2026-01-16 Gilead Sciences Inc Inhibidores de prmt5 y usos de los mismos
JP2026522894A (ja) 2023-06-30 2026-07-09 ギリアード サイエンシーズ, インコーポレイテッド Kras調節化合物
AU2024297978A1 (en) 2023-07-26 2026-02-05 Gilead Sciences, Inc. Parp7 inhibitors
CN121568935A (zh) 2023-07-26 2026-02-24 吉利德科学公司 Parp7抑制剂
US20250109147A1 (en) 2023-09-08 2025-04-03 Gilead Sciences, Inc. Kras g12d modulating compounds
EP4774280A1 (de) 2023-09-08 2026-07-15 Gilead Sciences, Inc. Kras-g12d-modulierende verbindungen
WO2025096589A1 (en) 2023-11-03 2025-05-08 Gilead Sciences, Inc. Prmt5 inhibitors and uses thereof
US20250230168A1 (en) 2023-12-22 2025-07-17 Gilead Sciences, Inc. Azaspiro wrn inhibitors
WO2025245003A1 (en) 2024-05-21 2025-11-27 Gilead Sciences, Inc. Prmt5 inhibitors and uses thereof
US20260098049A1 (en) 2024-08-12 2026-04-09 Gilead Sciences, Inc. Kras modulating compounds
US20260130893A1 (en) 2024-10-21 2026-05-14 Gilead Sciences, Inc. Prmt5 inhibitors and uses thereof
WO2026136515A1 (en) 2024-12-19 2026-06-25 Gilead Sciences, Inc. Parp7 inhibitors

Family Cites Families (115)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CU22545A1 (es) 1994-11-18 1999-03-31 Centro Inmunologia Molecular Obtención de un anticuerpo quimérico y humanizado contra el receptor del factor de crecimiento epidérmico para uso diagnóstico y terapéutico
US4526988A (en) 1983-03-10 1985-07-02 Eli Lilly And Company Difluoro antivirals and intermediate therefor
DE3587022T2 (de) 1984-02-17 1993-06-17 Genentech Inc Menschlicher transformationswachstumsfaktor und vorlaeufer oder fragment hiervon, zellen, dna, vektoren und verfahren zu ihrer herstellung, zusammensetzungen und produkte, die diese enthalten, sowie davon abgeleitete antikoerper und diagnostizierverfahren.
DE8411409U1 (de) 1984-04-11 1984-08-30 Dr.-Ing. Walter Frohn-Betriebe, 8000 München Entgasungsventil fuer lager- und/oder transportbehaelter
DE3587500T2 (de) 1984-12-04 1993-12-16 Lilly Co Eli Tumorbehandlung bei Säugetieren.
JPS62168137A (ja) * 1985-12-20 1987-07-24 Fuji Photo Film Co Ltd ハロゲン化銀カラ−写真感光材料およびその処理方法
JPH07106295B2 (ja) 1986-07-22 1995-11-15 エーザイ株式会社 調湿剤
CA1339136C (en) 1987-07-01 1997-07-29 Sailesh Amilal Varia Amorphous form of aztreonam
AU4128089A (en) 1988-09-15 1990-03-22 Rorer International (Overseas) Inc. Monoclonal antibodies specific to human epidermal growth factor receptor and therapeutic methods employing same
US4983615A (en) 1989-06-28 1991-01-08 Hoechst-Roussel Pharmaceuticals Inc. Heteroarylamino- and heteroaryloxypyridinamine compounds which are useful in treating skin disorders
US5180818A (en) 1990-03-21 1993-01-19 The University Of Colorado Foundation, Inc. Site specific cleavage of single-stranded dna
GB9105677D0 (en) 1991-03-19 1991-05-01 Ici Plc Heterocyclic compounds
US5367057A (en) 1991-04-02 1994-11-22 The Trustees Of Princeton University Tyrosine kinase receptor flk-2 and fragments thereof
JPH04341454A (ja) 1991-05-16 1992-11-27 Canon Inc シート収納装置
US5750376A (en) 1991-07-08 1998-05-12 Neurospheres Holdings Ltd. In vitro growth and proliferation of genetically modified multipotent neural stem cells and their progeny
JPH08501203A (ja) 1992-06-03 1996-02-13 ケイス・ウエスタン・リザーブ・ユニバーシティー 生理活性物質を連続的に適用するための包帯
JPH06153952A (ja) 1992-11-26 1994-06-03 Nobuaki Tamamaki 微量未知二重鎖dna分子の増幅、標識を行うための前処理方法
GB9323290D0 (en) 1992-12-10 1994-01-05 Zeneca Ltd Quinazoline derivatives
JPH07176103A (ja) 1993-12-20 1995-07-14 Canon Inc 光磁気記録再生システムならびにこれに用いる磁気ヘッド及び光磁気記録媒体
GB9326136D0 (en) 1993-12-22 1994-02-23 Erba Carlo Spa Biologically active 3-substituted oxindole derivatives useful as anti-angiogenic agents
US6811779B2 (en) 1994-02-10 2004-11-02 Imclone Systems Incorporated Methods for reducing tumor growth with VEGF receptor antibody combined with radiation and chemotherapy
JP3660391B2 (ja) 1994-05-27 2005-06-15 株式会社東芝 半導体装置の製造方法
JPH0848078A (ja) 1994-08-05 1996-02-20 Nippon Paper Ind Co Ltd 感熱記録体
US5656454A (en) 1994-10-04 1997-08-12 President And Fellows Of Harvard College Endothelial cell-specific enhancer
IL115256A0 (en) 1994-11-14 1995-12-31 Warner Lambert Co 6-Aryl pyrido (2,3-d) pyrimidines and naphthyridines and their use
US5658374A (en) 1995-02-28 1997-08-19 Buckman Laboratories International, Inc. Aqueous lecithin-based release aids and methods of using the same
US5624937A (en) 1995-03-02 1997-04-29 Eli Lilly And Company Chemical compounds as inhibitors of amyloid beta protein production
ATE446955T1 (de) 1995-03-30 2009-11-15 Pfizer Prod Inc Chinazolinone derivate
GB9508538D0 (en) 1995-04-27 1995-06-14 Zeneca Ltd Quinazoline derivatives
US5880141A (en) 1995-06-07 1999-03-09 Sugen, Inc. Benzylidene-Z-indoline compounds for the treatment of disease
JPH0923885A (ja) 1995-07-12 1997-01-28 Dai Ichi Seiyaku Co Ltd 遺伝子発現ライブラリー及びその製造法
US6346398B1 (en) 1995-10-26 2002-02-12 Ribozyme Pharmaceuticals, Inc. Method and reagent for the treatment of diseases or conditions related to levels of vascular endothelial growth factor receptor
DE69622183D1 (de) 1995-11-07 2002-08-08 Kirin Brewery Chinolinderivate und chinazolinderivate welche die autophosphorylierung des von blutplättchen abstammenden wachstumsfaktorrezeptors inhibiren und sie enthaltende pharmazeutische zusammensetzungen
GB9604361D0 (en) 1996-02-29 1996-05-01 Pharmacia Spa 4-Substituted pyrrolopyrimidine compounds as tyrosine kinase inhibitors
JPH09234074A (ja) 1996-03-04 1997-09-09 Sumitomo Electric Ind Ltd アダプター二本鎖dna及びそれを用いたdna増幅方法
EP0837063A1 (de) 1996-10-17 1998-04-22 Pfizer Inc. 4-Aminoquinazolinderivate
US6090556A (en) 1997-04-07 2000-07-18 Japan Science & Technology Corporation Method for quantitatively determining the expression of a gene
AU8283898A (en) 1997-06-30 1999-01-25 University Of Maryland At Baltimore Heparin binding-epidermal growth factor in the diagnosis of interstitial cystitis
JP3765918B2 (ja) 1997-11-10 2006-04-12 パイオニア株式会社 発光ディスプレイ及びその駆動方法
IL144461A0 (en) 1999-01-22 2002-05-23 Kirin Brewery Quinoline and quinazoline derivatives and pharmaceutical compositions containing them
JP3270834B2 (ja) 1999-01-27 2002-04-02 ファイザー・プロダクツ・インク 抗がん剤として有用なヘテロ芳香族二環式誘導体
EE05345B1 (et) 1999-02-10 2010-10-15 Astrazeneca Ab Kinasoliini derivaadid angiogeneesi inhibiitoritena
JP2000328080A (ja) 1999-03-12 2000-11-28 Shin Etsu Chem Co Ltd シートベルト用低摩擦化処理剤
YU13200A (sh) 1999-03-31 2002-10-18 Pfizer Products Inc. Postupci i intermedijeri za dobijanje anti-kancernih jedinjenja
EP1179541B1 (de) 1999-04-28 2004-06-16 Board Of Regents, The University Of Texas System Zusammensetzungen und Verfahren zur Krebsbehandlung durch die selektive Hemmung von VEGF
WO2001012600A1 (en) 1999-08-12 2001-02-22 Cor Therapeutics, Inc. INHIBITORS OF FACTOR Xa
JP2001131071A (ja) 1999-10-29 2001-05-15 Meiji Seika Kaisha Ltd 非晶質および非晶質を含有する医薬組成物
JP2003525595A (ja) 1999-11-01 2003-09-02 キュラゲン コーポレイション 脈管形成に含まれる差動発現遺伝子、それにコードされるポリペプチド、及びそれを用いた方法
CA2395461C (en) * 1999-12-22 2010-05-25 Sugen, Inc. Methods of modulating c-kit tyrosine kinase function with indolinone compounds
EP1243582A4 (de) 1999-12-24 2003-06-04 Kirin Brewery Chinolin- und chinazolinderivate sowie medikamente, die diese enthalten
DE60018216T2 (de) 1999-12-24 2006-02-16 Kyowa Hakko Kogyo Co., Ltd. Kondensierte purinderivate
HRP20020751B1 (hr) 2000-02-15 2011-01-31 Sugen Pirolom supstituirani 2-indolinoni kao inhibitori protein kinaze
JP3657203B2 (ja) 2000-04-21 2005-06-08 エーザイ株式会社 銅クロロフィリン塩含有液剤組成物
CA2409044C (en) * 2000-05-15 2013-02-19 Takeda Chemical Industries, Ltd. Improved recrystallization processes for obtaining anhydrous optically active lansoprazole
WO2001096390A2 (en) 2000-06-09 2001-12-20 Corixa Corporation Compositions and methods for the therapy and diagnosis of colon cancer
KR100600550B1 (ko) 2000-10-20 2006-07-13 에자이 가부시키가이샤 질소 함유 방향환 유도체
TWI283575B (en) 2000-10-31 2007-07-11 Eisai Co Ltd Medicinal compositions for concomitant use as anticancer agent
AU2002223684A1 (en) 2000-11-22 2002-06-03 Novartis Pharma Gmbh Combination comprising an agent decreasing vegf activity and an agent decreasing egf activity
WO2002072578A2 (en) * 2001-03-08 2002-09-19 Millennium Pharmaceuticals (homo) piperazine substituted quinolines for inhibiting the phosphorylation of kinases
JP3602513B2 (ja) 2001-04-27 2004-12-15 麒麟麦酒株式会社 アゾリル基を有するキノリン誘導体およびキナゾリン誘導体
EP1382604B1 (de) 2001-04-27 2005-12-28 Kirin Beer Kabushiki Kaisha Chinolinderivate mit einer azolylgruppe und chinazolinderivate
JP2003026576A (ja) 2001-05-09 2003-01-29 Eisai Co Ltd 味覚改善製剤
AU2002342335B2 (en) 2001-05-16 2006-02-02 Novartis Ag Combination comprising N-{5-[4-(4-methyl-piperazino-methyl)-benzoylamido]-2-methylphenyl}-4-(3-pyridyl)-2pyrimidine-amine and a chemotherapeutic agent
GB0119467D0 (en) 2001-08-09 2001-10-03 Smithkline Beecham Plc Novel compound
EP1451348B1 (de) 2001-09-10 2015-08-12 Meso Scale Technologies, LLC Verfahren, reagentien, kits und vorrichtungen zur proteinfunktionsanalyse
CA2460845A1 (en) * 2001-09-20 2003-03-27 Ab Science Use of potent, selective and non toxic c-kit inhibitors for treating interstitial cystitis
US20040266779A1 (en) 2001-09-27 2004-12-30 Anderson Kenneth C. Use of c-kit inhibitors for the treatment of myeloma
JP2005531488A (ja) 2001-10-09 2005-10-20 ザ・ユニバーシティ・オブ・シンシナティ 甲状腺癌を処置するためのegf受容体阻害剤
JP4383870B2 (ja) 2001-10-17 2009-12-16 協和発酵キリン株式会社 線維芽細胞増殖因子受容体自己リン酸化を阻害するキノリン誘導体およびキナゾリン誘導体並びにそれらを含有する医薬組成物
WO2003074045A1 (en) 2002-03-05 2003-09-12 Eisai Co., Ltd. Antitumor agent comprising combination of sulfonamide-containing heterocyclic compound with angiogenesis inhibitor
EP1488239A2 (de) 2002-03-20 2004-12-22 Dana-Farber Cancer Institute, Inc. Verfahren und verbindungen für die identifizierung, nachweis und behandlung von kleinzellen-lungenkarzinom
JPWO2003093238A1 (ja) 2002-05-01 2005-09-08 麒麟麦酒株式会社 マクロファージコロニー刺激因子受容体自己リン酸化を阻害するキノリン誘導体およびキナゾリン誘導体
UA77303C2 (en) 2002-06-14 2006-11-15 Pfizer Derivatives of thienopyridines substituted by benzocondensed heteroarylamide useful as therapeutic agents, pharmaceutical compositions and methods for their use
WO2004006862A2 (en) 2002-07-16 2004-01-22 Children's Medical Center Corporation A method for the modulation of angiogenesis
US20060004029A1 (en) 2002-08-30 2006-01-05 Akihiko Tsuruoka Nitrogen-containing aromatic derivatives
BR0315169A (pt) 2002-10-09 2005-08-23 Kosan Biosciences Inc Referência cruzada a pedidos de patente relacionados
GB0223380D0 (en) 2002-10-09 2002-11-13 Astrazeneca Ab Combination therapy
JP4749660B2 (ja) 2002-10-16 2011-08-17 武田薬品工業株式会社 安定な固形製剤
US8697094B2 (en) 2002-10-16 2014-04-15 Takeda Pharmaceutical Company Limited Stable solid preparations
WO2004039782A1 (ja) * 2002-10-29 2004-05-13 Kirin Beer Kabushiki Kaisha Flt3自己リン酸化を阻害するキノリン誘導体およびキナゾリン誘導体並びにそれらを含有する医薬組成物
CA2502979A1 (en) 2002-11-06 2004-05-21 Cyclacel Limited Pharmaceutical composition comprising a cdk inhibitor and gemcitabine
GB0226434D0 (en) 2002-11-13 2002-12-18 Astrazeneca Ab Combination product
AR042042A1 (es) 2002-11-15 2005-06-08 Sugen Inc Administracion combinada de una indolinona con un agente quimioterapeutico para trastornos de proliferacion celular
US7399866B2 (en) 2003-01-14 2008-07-15 Cytokinetics, Inc. Compounds, compositions, and methods
MXPA05009434A (es) 2003-03-05 2005-11-23 Celgene Corp Compuestos de difeniletileno y usos de los mismos.
EP1604665B1 (de) 2003-03-10 2011-05-11 Eisai R&D Management Co., Ltd. C-kit kinase-hemmer
JPWO2004081047A1 (ja) 2003-03-14 2006-06-29 大正製薬株式会社 モノクローナル抗体及びこれを産生するハイブリドーマ
US20070117842A1 (en) 2003-04-22 2007-05-24 Itaru Arimoto Polymorph of 4-[3-chloro-4-(cyclopropylaminocarbonyl)aminophenoxy]-7-methoxy-6- quinolinecarboxamide and a process for the preparation of the same
DE602004013792D1 (de) * 2003-08-15 2008-06-26 Ab Science Verwendung von c-kit-inhibitoren für die behandlung von typ-2-diabetes
EA200600495A1 (ru) 2003-09-23 2006-10-27 Новартис Аг Комбинация ингибитора vegf рецептора с химиотерапевтическим агентом
EP2210607B1 (de) 2003-09-26 2011-08-17 Exelixis Inc. N-[3-fluoro-4-({6-(methyloxy)-7-[(3-morpholin-4-ylpropyl)oxy]quinolin-4-yl}oxy)phenyl]-N'-(4-fluorophenyl)cyclopropane-1,1-dicarboxamid zur Behandlung von Krebs
JP4303726B2 (ja) 2003-11-11 2009-07-29 エーザイ・アール・アンド・ディー・マネジメント株式会社 ウレア誘導体およびその製造方法
RU2006122853A (ru) 2003-11-28 2008-01-10 Новартис АГ (CH) Производные диарилмочевины для лечения заболеваний, зависимых от протеинкиназы
BRPI0417302A (pt) 2003-12-05 2007-03-06 Compound Therapeutics Inc inibidores de receptores de fator de crescimento endotelial vascular do tipo 2
HUE025742T2 (hu) 2003-12-25 2016-04-28 Eisai R&D Man Co Ltd 4-(3-klór-4-(ciklopropilamino-karbonil)aminofenoxi)-7-metoxi-6-kinolin-karboxamid vagy szolvátja sójának kristálya és eljárás elõállításukra
KR100799534B1 (ko) 2004-02-27 2008-01-31 에자이 알앤드디 매니지먼트 가부시키가이샤 신규 피리딘 유도체 및 피리미딘 유도체(1)
KR20050091462A (ko) 2004-03-12 2005-09-15 한국과학기술연구원 푸로피리미딘 화합물 및 이를 포함하는 ddr2 티로신키나아제 활성 저해제
JP4341454B2 (ja) 2004-04-08 2009-10-07 トヨタ自動車株式会社 固体電解質型燃料電池の製造方法
JP2008501652A (ja) 2004-06-03 2008-01-24 エフ.ホフマン−ラ ロシュ アーゲー ゲムシタビン及びegfrインヒビターによる治療
US8772269B2 (en) 2004-09-13 2014-07-08 Eisai R&D Management Co., Ltd. Use of sulfonamide-including compounds in combination with angiogenesis inhibitors
WO2006030941A1 (ja) 2004-09-13 2006-03-23 Eisai R & D Management Co., Ltd. スルホンアミド含有化合物の血管新生阻害物質との併用
US8969379B2 (en) 2004-09-17 2015-03-03 Eisai R&D Management Co., Ltd. Pharmaceutical compositions of 4-(3-chloro-4-(cyclopropylaminocarbonyl)aminophenoxy)-7=methoxy-6-quinolinecarboxide
US20060079494A1 (en) 2004-09-27 2006-04-13 Santi Daniel V Specific kinase inhibitors
CA2586420A1 (en) 2004-11-22 2007-04-12 King Pharmaceuticals Research & Development, Inc. Enhancing treatment of cancer and hif-1 mediated disoders with adenosine a3 receptor antagonists
US7612200B2 (en) 2004-12-07 2009-11-03 Locus Pharmaceuticals, Inc. Inhibitors of protein kinases
JP5106098B2 (ja) 2005-02-28 2012-12-26 エーザイ・アール・アンド・ディー・マネジメント株式会社 スルホンアミド化合物の抗癌剤との新規併用
PL1859793T3 (pl) 2005-02-28 2011-09-30 Eisai R&D Man Co Ltd Nowe połączone zastosowanie związku sulfonamidowego w leczeniu choroby nowotworowej
US7550483B2 (en) 2005-06-23 2009-06-23 Eisai R&D Management Co., Ltd. Amorphous salt of 4-(3-chloro-4-(cyclopropylaminocarbonyl)aminophenoxy)-7-methoxy-6-quinolinecarboxamide and process for preparing the same
KR100951607B1 (ko) 2005-06-23 2010-04-09 에자이 알앤드디 매니지먼트 가부시키가이샤 4-(3-클로로-4-(시클로프로필아미노카르보닐)아미노페녹시)-7-메톡시-6-퀴놀린카르복사미드의 비정질 염 및 그 제조방법
WO2007014335A2 (en) 2005-07-27 2007-02-01 The University Of Texas System Combinations comprising gemcitabine and tyrosine kinase inhibitors for the treatment of pancreatic cancer
JP5066446B2 (ja) 2005-08-01 2012-11-07 エーザイ・アール・アンド・ディー・マネジメント株式会社 血管新生阻害物質の効果を予測する方法
JP4989476B2 (ja) 2005-08-02 2012-08-01 エーザイ・アール・アンド・ディー・マネジメント株式会社 血管新生阻害物質の効果を検定する方法
KR101353763B1 (ko) 2005-11-07 2014-01-21 에자이 알앤드디 매니지먼트 가부시키가이샤 혈관 신생 저해 물질과 c―kit 키나아제 저해 물질의병용
US20090247576A1 (en) 2005-11-22 2009-10-01 Eisai R & D Management Co., Ltd. Anti-tumor agent for multiple myeloma
CN104706637A (zh) 2006-05-18 2015-06-17 卫材R&D管理有限公司 针对甲状腺癌的抗肿瘤剂

Also Published As

Publication number Publication date
JPWO2004080462A1 (ja) 2006-06-08
US7994159B2 (en) 2011-08-09
EP1604665A4 (de) 2009-05-13
EP1604665A1 (de) 2005-12-14
WO2004080462A1 (ja) 2004-09-23
EP1604665B1 (de) 2011-05-11
US20040253205A1 (en) 2004-12-16

Similar Documents

Publication Publication Date Title
EP1604665A4 (de) C-kit kinase-hemmer
TW200610531A (en) Phthalazine derivatives as PARP inhibitors
MX2009012345A (es) Derivados de 3,3-espiroindolinona.
TW200616978A (en) Quinazolinone derivatives as parp inhibitors
GEP20094785B (en) Pyrrolopyrazoles, potent kinase inhibitors
MX2009004766A (es) Derivados de espiroindolinona.
MX2009002735A (es) Derivados de oxindol como agentes anticancerigenos.
SG154432A1 (en) Quinazolinedione derivatives as parp inhibitors
TW200740815A (en) P38 MAP kinase inhibitors and methods for using the same
TW200618800A (en) Heterocyclic compounds
TW200642689A (en) Immunosuppressive agent and anti-tumor agent comprising heterocyclic compound as active ingredient
MX2009004441A (es) Derivados de indazol utiles como inhibidores de las isoformas de higado.
WO2006084017A3 (en) Phenyl-substituted pyrimidine compounds useful as kinase inhibitors
MX2007005933A (es) Compuestos de acetamida como fungicidas.
CY1107846T1 (el) Παραγωγα κιναζολινονης χρησιμα ως βανιλλοειδεις ανταγωνιστες
TW200833324A (en) Sulfonamide derivatives
MY153727A (en) Pyridazinone derivatives
TW200745032A (en) Novel heterobicyclic derivatives
MX2010009927A (es) Derivados de espiroindolinona.
GB0308201D0 (en) Novel compounds
NO20061317L (no) Imidazopyridinderivater som induserbare NO-syntaseinhibatorer
MY148644A (en) New pharmaceutical compounds
ATE469647T1 (de) Thienoä3,2-cüpyridin-7-carbonsäure-derivate
NO20061344L (no) Imidazopyridinderivater som induserbare NO-syntaseoinhibitorer
DE602004014523D1 (de) Imidazoä4,5-büpyridinderivate als inhibitoren der induzierbaren no-synthase

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties